Clinical Trial Update: Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating a recombinant live-attenuated RSV vaccine in seronegative infants to assess infectivity, safety, and immunogenicity; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• D46/NS2/N/ΔM2-2-HindIII

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2019-06-14